One of the keys to maintaining tumor vascular normalization is to keep the balance between proangiogenic factors and antiangiogenic factors: for one thing, although inhibiting proangiogenic factors such as VEGF and Ang2 have been extensively studied to induce vascular normalization, there is, owing to their dose dependence, the lack of advanced technologies or biomarkers to determine the window for vascular normalization posing the major challenge; for another, angiostatic factors such as TNF, TSP-1, and endostar have shown the potential to promote vascular normalization. The gene discussed is VEGFA; the disease is neoplasm.